B+
Bull case
25%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
CRMD
CorMedixBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 consolidated revenue was $101.9 million, including $66.1 million from DefenCath, and management raised 2026 adjusted EBITDA guidance to $125 million–$140 million while maintaining revenue guidance of $325 million–$345 million. Sustained dialysis utilization and REZZAYO regulatory progress could support upside [#SEC-8K-2026-08-13].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
Commercial expansion and clinical development spending could pressure cash generation despite the $256.7 million cash and short-term investment balance reported at June 30 [#SEC-8K-2026-08-13].
Momentum
62
Value
72
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.00 · Bull $10.50 · Bear $4.75Analysis 2026-10-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $14.60
Why
Momentum62 · Δ7d -4.8
Value72 · Δ7d -0.3
Sentiment46 · Δ7d -8.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.3.
Contradictions & invalidation
- • Commercial expansion and clinical development spending could pressure cash generation despite the $256.7 million cash and short-term investment balance reported at June 30 [#SEC-8K-2026-08-13].
- • DefenCath utilization and pricing may not translate the new dialysis-operator agreement into durable revenue under post-TDAPA reimbursement [#SEC-8K-2026-08-13].
- • The Q3 sNDA submission target has passed without confirmation in the checked sources.
Catalyst clock
2026-12-31
REZZAYO prophylaxis sNDA status
Lead driver: Value · See fundamentals
Momentum
62
8% active weight
Current posture
7d trendSoftening
Δ7d
-4.8
Δ21d
+15.5
Value
72
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.9
Sentiment
46
45% active weight
Current posture
7d trendSoftening
Δ7d
-8.0
Δ21d
-21.0
Why this grade
Composite grade B. Momentum 61.7 / Value 71.7 / Sentiment 46.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-18. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.75
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$611.86M
Beta
1.40
Shares Out
77.94M
P/E (TTM)
5.9
P/S (TTM)
4.48
P/FCF (TTM)
12.91
Rev YoY
+156.5%
EPS YoY
+1.9%
Gross Margin
+82.8%
Op Margin
+47.0%
Net Debt
-$273K
Current Ratio
2.56
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data